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httpcense.Abstract Lung cancer accounts for one-third of all cancer-related deaths worldwide. Glycosami-
noglycans and matrix metalloproteinase-7 (MMP-7) have been found to be involved in cancer.
The aim of our study was to evaluate the clinical signiﬁcance of urinary glycosaminoglycans and
MMP-7 in lung cancer patients in order to explore their potential diagnostic utility and predicting
ability with respect to the different clinicopathological parameters.
Urine samples used in the assay of glycosaminoglycans and MMP-7 were collected from 70 lung
cancer patients (45 squamous cell lung cancer and 25 adenocarcinoma). Control subjects were 15
age and sex matched non smokers.
The malignant group mainly adenocarcinoma type showed signiﬁcant increase in urinary glycos-
aminoglycans and MMP-7 compared to control group. Regarding the different clinicopathological
factors, urinary glycosaminoglycans and MMP-7 showed signiﬁcant increase with the histological
grades and clinical stages (p< 0.05, p< 0.05 respectively). The best cut-off values for glycosami-
noglycans and MMP-7 determined by Receiver operating characteristic (ROC) curve were 67.5 lg/
mg creatinine and 10.05 ng/mg creatinine respectively. The sensitivity and speciﬁcity were 91.4%
and 86.7% for glycosaminoglycans and 71.4% and 86.7% for MMP-7. The combined assay of
the two parameters raised the overall positivity rate to 88.9% and 94.7% regarding grade 1 and
stage I respectively.
In conclusion, our ﬁndings can indicate that urinary glycosaminoglycans and MMP-7 can be
potential non invasive helpful markers in lung cancer patients.
ª 2013 The Egyptian Society of Chest Diseases and Tuberculosis. Production and hosting by Elsevier B.V.
Open access under CC BY-NC-ND license.904312/1223180464.
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Lung cancer has become the number one killer among cancers
worldwide [1].
In spite of aggressive therapy available today, the prognosis
of lung cancer patients is generally very poor due to lack of
biomarkers for the reliable detection of malignant lung tumorsis. Production and hosting by Elsevier B.V. All rights reserved.
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identify lung cancer is important to facilitate earlier diagnosis
of primary or recurring cancers thus leading to more effective
treatment and improved prognosis [3].
The extracellular matrix (ECM) not only provides tissue
support, but its functional macromolecules are also involved
in the regulation of cell properties and function. This is mainly
due to interactions between ECM components and cell-surface
receptors, growth factors and cytokines. Therefore, ECM con-
stituents are closely involved in the cellular and molecular
mechanisms of cancer cells, and affect their adhesion and
migration as well as their invasiveness and metastatic poten-
tial. Proteoglycans, which make up a major part of the
ECM, are heavily glycosylated glycoproteins. The speciﬁc type
of polysaccharides attached to proteoglycans are called glycos-
aminoglycans (GAGs). GAGs, are long, linear and highly
charged, heterogeneous polysaccharides that are composed
of a variable number of repeating disaccharide units and most
of them, as their name implies, have a sweet taste. The GAGs
are involved in signaling cascades regulating angiogenesis,
invasion and metastasis of malignant cells [4].
In the lung, GAGs support the structure of the interstitium,
the subepithelial tissue and the bronchial walls, and are se-
creted in the airway secretions. Besides maintaining lung tissue
structure, GAGs also play an important role in lung function
as they regulate hydration and water homeostasis, modulate
the inﬂammatory response and inﬂuence lung tissue repair
and remodeling [5].
Metalloproteinases are secreted proteins belonging to a
family of zinc metalloendopeptidases that have the capacity
to cleave ECM. They can modify both cell–cell and cell–
ECM interactions by the proteolysis of cell surface growth fac-
tors and adhesion receptors. Because their substrates are di-
verse, metalloproteinases are involved in a variety of
homeostatic functions, such as bone remodeling, wound heal-
ing, and several aspects of immunity. However, metallopro-
teinases are also involved in a number of pathological
processes, such as tumor progression, ﬁbrosis, chronic inﬂam-
mation and tissue destruction [6]. Matrix metalloproteinase-7
(MMP-7) is the smallest one of the matrix metalloproteinases.
It has been found that MMP-7 is highly expressed in glandular
epithelial cells and carcinoma of cells of epithelial origin and
that it promotes cell migration [7].
In cancer, the study of GAGs [8] and MMP-7 [9] has been
primarily twofold: ﬁrst, in aiding diagnosis and second, in
developing alternative treatments. Therefore, this study was
conducted to evaluate the clinical signiﬁcance of urinary
GAGs and MMP-7 in lung cancer patients, also their potential
diagnostic utility and predicting ability with respect to the dif-
ferent clinicopathological parameters.
Materials and methods
Patients and tissue samples
This study has complied with the principles laid down in the
Declaration of Helsinki, 1964. The studied groups included
70 lung cancer patients (45 squamous cell lung cancer and 25
adenocarcinoma patients). Fifty eight were males and 12 were
females. Their ages ranged from 41 to 75 years old (61 ± 7.2).
Fifteen age matched (62 ± 8) and sex matched non smokeradults were also collected and acted as the control. The control
subjects presented with hemoptysis (n= 8), with chronic per-
sistent cough (n= 3) with no obvious evident explanations,
with foreign body aspiration (n= 2) and 2 subjects with post-
operative lobe or segmental atelectasis (therapeutic broncho-
scope). Tissue samples were obtained from all subjects who
underwent ﬁberoptic bronchoscopy in Ain Shams University
Hospitals in Cairo, Egypt. Patients did not receive any form
of therapy before bronchoscopy. Specimens were ﬁxed in
10% formalin solution for histological examination. Lung can-
cer was staged using a widely used classiﬁcation system and
graded by the Nottingham grading system [10].
The urinary levels of GAGs and MMP-7 in the malignant
group were compared with the clinicopathological characteris-
tics, including smoking status, histological grade and TNM
stage.
Procedure of ﬁberoptic bronchoscopy and bronchial biopsy
Patients and controls were prepared for elective ﬁberoptic
bronchoscopy. Written consent was obtained after a reassuring
explanation of the steps of bronchoscope. Prior to the proce-
dure, the general condition and vital signs as well as arterial
blood gas and pulmonary function test were assessed. Exclu-
sion of any active ischemic heart disease, severe respiratory
insufﬁciency even on supplemental oxygen and coagulation
disorders was done. They were fasting for at least 6 hours be-
fore the procedure and three hours after to avoid any possible
complications. It is usual to give the patient supplemental oxy-
gen via nasal cannula and to monitor the saturation by pulse
oximetry.
Atropine sulphate 0.6 mg was given intramuscularly 30 min
before the procedure to reduce bronchial secretions and to
block a possible vasovagal reﬂex. About 20–40 min after pre-
medication (atropine sulphate), a 4% lidocaine (lignocaine)
sprayed into both nostrils and the patient’s mouth. Having
anaesthetized the upper respiratory tract, the shaft of the bron-
choscope is well lubricated with 2% lidocaine gel and is ad-
vanced into a nostril under direct vision, through the widest
visible opening between the turbinates. If the bronchoscope
does not advance easily it should be withdrawn and the other
nostril tried, if failed, mouth approach should be tried. As the
instrument is advanced, the tip is ﬂexed downwards and the
epiglottis and larynx come into view. The position and move-
ment of the vocal cords with respiration is noted and the pa-
tient is asked to say ‘‘eeee’’, so that full apposition of the
cords can be observed and vocal cord paralysis conﬁrmed or
excluded. Additional 2.5 ml aliquots of 2% lidocaine (50 mg)
may be instilled down the suction channel of the bronchoscope
to facilitate passage of the bronchoscope through the vocal
cords to the trachea and trachea. Tracheobronchial mucosa
is normally smooth and pink, the main carina and subcarinae
(bronchial or segmental spurs) are usually sharp. Thorough
bronchoscopic evaluation we can localize endobronchial
masses.
A centrally placed tumor may be clearly visible as an endo-
bronchial mass of tissue that may partially or totally occlude
the lumen in which it is situated. Loss of the usual mucosal lus-
ter and presence of roughened surface with ulceration and
necrosis of the overlying mucosa may alert the expert
bronchoscopist to an early inﬁltrative or neoplastic process.
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lowed by histopathological examination.
Bleeding may occur during biopsy, this is an encourage-
ment to the bronchoscopist to spray the suspected lesion with
a bolus of 5 ml 1:20000 epinephrine (adrenaline) solution be-
fore taking another repeated biopsy.
Urine samples collection and processing
Each participant was asked to void early morning urine sample
in a sterile container. Each urine sample was centrifuged at
3000 rpm for 25 min and the supernatant was divided into
two aliquots stored at 80 C until used; one without preser-
vative used for measurement of MMP-7 using MMP-7 Quan-
tikine ELISA kit (R&D Systems Inc., Minneapolis, USA) and
creatinine using creatinine Biolabo kit (BIOLABO SA, Maizy,
France) according to manufacturers’ instructions and the sec-
ond aliquot was preserved by the immediate addition of meth-
anol (0.1 ml methanol/10 ml urine) used for measurement of
glycosaminoglycans.
Quantitative determination of urinary glycosaminoglycans
Urinary glycosaminoglycans were precipitated according to
the method of Ferrante [11], and adapted by Pennock [12].
Twenty ﬁve milliliters of each preserved sample was centri-
fuged at 3000 rpm for 25 min and 5 ml of supernatant was pre-
cipitated with 10% cetylpyridinium chloride purchased from
Sigma–Aldrich Chemie GmbH, Steinheim, Germany. The pre-
cipitate was collected by centrifugation, washed twice with
95% ethanol containing 10% potassium acetate and dissolved
in 1 ml of 0.05 M NaOH. Glycosaminoglycans were deter-
mined in urine according to the previously described method
of Whitley et al. [13], using chondroitin sulfate sodium salt
(from shark cartilage, no. immunoassay C4384) purchased
from Sigma–Aldrich Chemie GmbH, Steinheim, Germany as
a standard. Brieﬂy, a 10X stock solution (0.35 mmol/L) of
1,9-dimethylmethylene blue (DMB) dye (Sigma-Aldrich Che-
mie GmbH, Steinheim, Germany) was made by dissolving
122 mg of dye in 10 ml of 95% ethanol which was then diluted
to1 liter with sodium formate buffer (pH 3.5, 0.2 mmol/L).
40 ll of each urine sample (or standard) was mixed withFigure 1 ROC curve of urinary GAGs1.0 ml of freshly prepared working DMB dye (1X). The absor-
bance was measured after 30 min incubation at 535 nm against
buffer. The measured values were corrected for reagent blank
and sample blank absorbances. Glycosaminoglycan concentra-
tions (lg/ml) were determined from the standard curve then
normalized to urinary creatinine and expressed in lg GAGs/
mg creatinine.
Statistical analysis
The analysis was done using the Statistical Package for the So-
cial Sciences (SPSS software version 19). Data are expressed as
mean ± standard deviation (SD). The studied parameters
were related to the clinicopathological parameters using ANO-
VA test. Correlation between variables was performed by
Pearson test. For the above comparisons, p< 0.05 was consid-
ered statistically signiﬁcant. Receiver operating characteristic
(ROC) curve determined the threshold value for optimal sensi-
tivity and speciﬁcity, which was constructed by calculating the
true positive fraction (sensitivity percent) and false positive
fraction (100-speciﬁcity) of markers at several cut off points.
Results
The studied groups included 70 lung cancer patients (45 squa-
mous cell lung cancer and 25 adenocarcinoma patients) and 15
lung tissue samples from non smoker control adults and their
clinicopathological factors are shown in Fig. 1 and Table 1.
Clinical sample analysis
Urinary concentrations of GAGs and MMP-7 were measured
in both the malignant and control groups (Tables 2 and 3). The
mean urinary GAGs and MMP-7 increased signiﬁcantly in the
malignant group (125.2 ± 46.7 and 14.0 ± 5.1 respectively)
versus the control group (40.8 ± 15.6 and 5.8 ± 2.1 respec-
tively, p< 0.01) Table 2.
The mean levels increased signiﬁcantly in adenocarcinoma
patients compared to squamous cell carcinoma patients
(168.1 ± 36.6 and 102 ± 33.5 respectively for urinary GAGs,
17.4 ± 5.7 and12.1 ± 4.7 respectively for MMP-7, p< 0.01),
Table 3.and MMP-7 in lung cancer patients.










Male 12 (80%) 38 (54.3%) 22 (31.4%)
Female 3 (20%) 7 (10%) 3 (4.3%)
Non smoker – 19 (27.1%) 4 (5.7%)
Smoker 26 (37.2%) 21 (30.0%)
Aﬀected lung
Right lung – 29 (41.4%) 18 (25.7%)
Left lung 16 (22.9%) 7 (10%)
Aﬀected lobe
Upper lobe – 29 (41.4%) 15 (21.4%)
Middle lobe 11 (15.7%) 3 (4.3%)
Lower lobe 5 (7.2%) 7 (10%)
Grade; No. (%)
Grade 1 – 7 (10%) 2 (2.9%)
Grade 2 30 (42.9%) 8 (11.4%)
Grade 3 8 (11.4%) 15 (21.4%)
Stages; No. (%)
Stage I – 16 (22.9%) 3 (4.3%)
Stage II 13 (18.5%) 11 (15.7%)
Stage III 16 (22.9%) 11 (15.7%)
Tumor size
<3 cm – 28 (40%) 10 (14.3%)
>3 cm 17 (24.3%) 15 (21.4%)
Table 3 Urinary levels of GAGs and MMP-7 in squamous





group (mean ± SD)
GAGs (lg/mg creatinine) 102 ± 33.5 168.1 ± 36.6**
MMP-7 (ng/mg creatinine) 12.1 ± 4.7 17.4 ± 5.7**
** p< 0.01 is highly signiﬁcant;
** p< 0.01 versus squamous cell carcinoma.
Table 2 Urinary levels of GAGs and MMP-7 in the malig-





GAGs (lg/mg creatinine) 40.8 ± 15.6 125.2 ± 46.7**
MMP-7 (ng/mg creatinine) 5.8 ± 2.1 14.0 ± 5.1**
** p< 0.01 is highly signiﬁcant;
**p< 0.01 versus control group.
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Optimal cut-off points were 67.5 lg/mg creatinine and
10.05 ng/mg creatinine for urinary GAGs and MMP-7 respec-
tively. The best cut-off values were estimated to maximize the
sum of sensitivity and speciﬁcity, Table 4.
The relation between investigated marker and
clinicopathological factors
The levels of urinary GAGs and MMP-7 in relation to clinico-
pathological characteristics are shown in Table 5. There wasTable 4 Sensitivity and speciﬁcity of urinary GAGs and MMP-7 b
Parameter Cut-oﬀ Sensitivity (
GAGs (lg/mg creatinine) 67.5 91.4
MMP-7 (ng/mg creatinine) 10.05 71.4no signiﬁcant relation between both parameters and smoking
status (p> 0.05). However, There was signiﬁcant relation be-
tween investigated parameters and the different histological
grades and clinical stages (p< 0.05). The positivity rate of
combined assay of both parameters (number of cases having
urinary level of GAGs and/or MMP-7 higher than the cut-
off value of the corresponding parameter) was 88.9%, 89.5%
and 91.3% in grade 1, 2 and 3 respectively, while it was
94.7%, 91.7% and 92.6% in stage I, II and III respectively.
Correlation between investigated parameters
Concerning the level of the investigated parameters to each
other, there was a signiﬁcant positive correlation (r= 0.544),
Table 6.
Discussion
The investigation of the role that GAGs and MMP-7 plays in
cancer has been the focus of much recently done studies.
Previous reports showed signiﬁcant increase of the urinary
GAGs excretion in patients with bladder cancer compared to
normal subjects [14,15] and signiﬁcant increase of serum
GAGs levels in lymphoma patients compared to control sub-
jects [16]. As regards lung, studies demonstrated an increase
of GAGs excretion in urine of asthmatic subjects [17,18]. In
lung cancer, reports demonstrated an increase in the total
amount of GAGs in serum of patients of lung cancer com-
pared to that of healthy subjects [19], also reported an increase
of GAGs in lung cancer tissues compared to normal lung tis-
sues and that this increase was accompanied by changes in
the composition of GAGs [20]. Serum and tissue expression
levels of MMP-7 were found to be elevated in many cancers
like prostatic [21] and gastric [22]. In lung cancer MMP-7
was found to be expressed by lung tumor cells of all histolog-
ical types at various frequencies [23,24] but to our knowledge
no study has been done to evaluate the clinical role of urinary
GAGs and MMP-7 in lung cancer diagnosis and progression.
Therefore, urinary levels of GAGs and MMP-7 in 70 lung
cancer patients and 15 healthy age-matched subjects were esti-
mated in this study. Our results showed that the mean urinary
GAGs (lg/mg creatinine) and MMP-7 (ng/mg creatinine) wasy using receiver operating characteristic (ROC) curve.
%) Speciﬁcity (%) Area under ROC curve
86.7 0.933
86.7 0.828
Table 5 Relation between GAGs and MMP-7 urinary levels and clinicopathological factors.
Factors Urinary GAGs Urinary MMP-7 Urinary GAGs and MMP-7
Mean ± SD Positivity rate Mean ± SD Positivity rate Overall positivity rate
Smoking
Non smokers (n= 23) 99.47 ± 32.84 18 (78.3%) 11.6 ± 5.5 15(65.2%) 21 (91.3%)
Smokers (n= 47) 141.64 ± 47.21 42 (89.4%) 15.1 ± 3.6 35(74.5%) 45 (95.7%)
Grade
Grade 1 (n= 9) 77.6 ± 25.52 7 (77.8%) 10.8 ± 3.9 6 (66.7%) 8 (88.9%)
Grade 2(n= 38) 107.93 ± 32.32 33 (86.8%) 12.8 ± 4.9 27 (71%) 34 (89.5%)
Grade 3 (n= 23) 170.77 ± 34.56 20 (87%) 17.2 ± 5.1 17 (73.9%) 21 (91.3%)
p< 0.05* p< 0.05*
Stages
Stage I (n= 19) 110.91 ± 30.94 15 (78.9%) 12.7 ± 4.2 13 (68.4%) 18 (94.7%)
Stage II(n= 24) 111.23 ± 37.24 21 (87.5%) 11.6 ± 5.1 16 (66.7%) 22 (91.7%)
Stage III(n= 27) 149.93 ± 55.79 24 (88.9%) 17.1 ± 4.3 21 (77.8%) 25 (92.6%)
p< 0.05* p< 0.05*
* p< 0.05 is signiﬁcant.
Table 6 Correlation between the investigated parameters.
MMP-7
GAGs Pearson correlation 0.544*
* Correlation is signiﬁcant at p< 0.05 level.
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and 14.0 ± 5.1 respectively) versus the control group
(40.80 ± 15.6 and 5.8 ± 2.1 respectively, p< 0.01). We found
also that the mean level increased signiﬁcantly in adenocarci-
noma patients compared to squamous cell carcinoma patients
(168.1 ± 36.6 versus 102 ± 33.5 for urinary GAGs and
17.4 ± 5.7 versus 12.1 ± 4.7 for urinary MMP-7, p< 0.01).
This result was in agreement with previous reports [23,24]
which demonstrated that the expression of lung tumor cells
for MMP-7 was signiﬁcantly higher in adenocarcinoma type.
Regarding the different clinicopathological factors, the
mean urinary levels of GAGs and MMP-7 showed signiﬁcant
increase with the different histological grades and clinical
stages (p< 0.05, p< 0.05 respectively) which was in agree-
ment with many reports which found signiﬁcant correlation
between the urinary levels of GAGs and the different stages
and grades of bladder cancer [14,15]. The highest mean levels
of investigated parameters were detected in grade 3 and stage
III compared to grades (1 and 2) and stages (I and II). We also
found a signiﬁcant positive correlation between urinary GAGs
and MMP-7 (r= 0.544). The combined measurement of uri-
nary GAGs and MMP-7 increased the positivity rate for lung
cancer in respect to the different stages and grades.
Conclusion
Our ﬁndings suggested that urinary GAGs and MMP-7 in-
creased signiﬁcantly in lung cancer patients mainly in adeno-
carcinoma type and with the different histological grades and
clinical stages of the disease. They also showed high sensitivity
and speciﬁcity as well as high positivity rates as regards the dif-
ferent clinicopathological parameters especially with combinedmeasurement of the two parameters. This can indicate that uri-
nary GAGs and MMP-7 can be potential non invasive helpful
markers in lung cancer which provide a new biochemical ap-
proach for detecting and monitoring the pathogenesis of lung
cancer and ultimately, improve patient’s prognosis and quality
of life. Further studies on a large cohort of patients will be nec-
essary to conﬁrm these ﬁndings, also the types and structural
changes of excreted GAGs in the urine of lung cancer patients
should be investigated for the development of alternative lung
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